This company has been marked as potentially delisted and may not be actively trading. Altamira Therapeutics (CYTO) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CYTO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Altamira Therapeutics Ltd. (CYTOF) Q4 2024 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comFull Year 2024 Altamira Therapeutics Ltd Earnings CallMay 1, 2025 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTOF)April 11, 2025 | finance.yahoo.comAltamira Therapeutics Amends Revenue Sharing Agreement with Altamira MedicaMarch 10, 2025 | tipranks.comAltamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray PatentMarch 7, 2025 | markets.businessinsider.comAltamira Therapeutics Ltd (CYTOF)February 22, 2025 | investing.comAltamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting StrategiesJanuary 22, 2025 | markets.businessinsider.comAltamira Therapeutics Ltd. (CYTO) stock forecast and price targetJanuary 19, 2025 | finance.yahoo.comAltamira Therapeutics Ltd: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNAJanuary 2, 2025 | finanznachrichten.deAltamira Therapeutics Transitions to OTCQB Following Nasdaq DelistingDecember 21, 2024 | markets.businessinsider.comAltamira Therapeutics Announces Transition from NASDAQ to OTC MarketsDecember 20, 2024 | globenewswire.comAltamira Therapeutics Provides Update on Nasdaq ListingOctober 4, 2024 | globenewswire.comAltamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SpraySeptember 27, 2024 | globenewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call TranscriptSeptember 26, 2024 | msn.comAltamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ...September 25, 2024 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call TranscriptSeptember 24, 2024 | seekingalpha.comAltamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsSeptember 24, 2024 | globenewswire.comNuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East AsiaSeptember 23, 2024 | finance.yahoo.comLondon's SMEs must get the connectivity they deserve to thrive and growSeptember 21, 2024 | msn.comAltamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024September 20, 2024 | globenewswire.comAltamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingSeptember 19, 2024 | globenewswire.comAltamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingSeptember 17, 2024 | globenewswire.comAltamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11September 3, 2024 | globenewswire.comREPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)August 26, 2024 | globenewswire.comAltamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkAugust 23, 2024 | globenewswire.comAltamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesAugust 16, 2024 | globenewswire.comAltamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsAugust 12, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesJuly 19, 2024 | globenewswire.comAltamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementJune 20, 2024 | globenewswire.comAltamira Therapeutics Provides Business UpdateMay 28, 2024 | globenewswire.comWhat's Going On With Altamira Therapeutics Stock?May 23, 2024 | msn.comAltamira stock soars 45% on Bentrio social media postingsMay 23, 2024 | msn.comAltamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalMay 23, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationMay 1, 2024 | globenewswire.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | msn.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 24, 2024 | globenewswire.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 15, 2024 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 10, 2024 | finance.yahoo.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024April 4, 2024 | globenewswire.comAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 25, 2024 | finanznachrichten.deCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 25, 2024 | markets.businessinsider.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | msn.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 25, 2024 | globenewswire.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | marketwatch.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | msn.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 24, 2024 | finance.yahoo.com Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTO Media Mentions By Week CYTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTO News Sentiment▼0.000.96▲Average Medical News Sentiment CYTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTO Articles This Week▼00▲CYTO Articles Average Week Get the Latest News and Ratings for CYTO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Altamira Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies DRMA News CNSP News SHPH News GRI News JAGX News GTBP News ENTO News BDRX News RDHL News QLGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTO Stock Alerts